Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.
- Published In:
- Journal of diabetes and its complications, 39(3), 108975 (2025)
- Authors:
- Xu, Qian(2), Qiu, Xuan, Di, Hailing, Li, Zhongkang, Liu, Zanchao, Liu, Kuanzhi
- Database ID:
- RPEP-14272
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14272APA
Xu, Qian; Qiu, Xuan; Di, Hailing; Li, Zhongkang; Liu, Zanchao; Liu, Kuanzhi. (2025). Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.. Journal of diabetes and its complications, 39(3), 108975. https://doi.org/10.1016/j.jdiacomp.2025.108975
MLA
Xu, Qian, et al. "Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.." Journal of diabetes and its complications, 2025. https://doi.org/10.1016/j.jdiacomp.2025.108975
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide improves senescence and ameliorating diabetic sa..." RPEP-14272. Retrieved from https://rethinkpeptides.com/research/xu-2025-liraglutide-improves-senescence-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.